Kairos Pharma, Ltd. (KAPA) has received a new Buy rating, initiated by H.C. Wainwright analyst, Joseph Pantginis.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Kairos Pharma, Ltd.’s potential in addressing cancer drug resistance and enhancing immune function. The company is developing innovative drugs targeting resistance mechanisms in various cancers, with a focus on their lead asset, ENV-105, which is in clinical trials for treating metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC).
ENV-105 is designed to reverse cancer drug resistance by leveraging synthetic lethality, potentially improving the effectiveness of existing treatments without introducing entirely new modalities. This approach presents a significant market opportunity, especially given the large market sizes for prostate and lung cancer therapeutics. Additionally, with upcoming clinical milestones and a promising pipeline of preclinical candidates, Kairos Pharma is positioned for long-term growth, making it an attractive investment opportunity according to Pantginis.
In another report released on March 31, Maxim Group also reiterated a Buy rating on the stock with a $4.00 price target.
KAPA’s price has also changed moderately for the past six months – from $1.320 to $0.918, which is a -30.45% drop .